<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>ado-trastuzumab emtansine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB05773</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Ado-trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) as an investigational drug, is a first-in-class HER2 antibody drug conjugate (<span class="caps">ADC</span>) comprised of Genentech&#8217;s trastuzumab antibody linked to ImmunoGen&#8217;s cell-killing agent, DM1. T-DM1 combines two strategies&#8212; anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)&#8212;to produce cell cycle arrest and apoptosis. Ado-trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. The <span class="caps">FDA</span> label has two precautions. First that ado-trastuzumab emtansine and trastuzumab cannot be interchanged. Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB05773/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB05773/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB05773.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB05773.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB05773.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB05773.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB05773.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB05773">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>trastuzumab emtansine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Trastuzumab-DM1</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>trastuzumab-MCC-DM1</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Kadcyla</td><td>Genentech </td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antineoplastic-agents">Antineoplastic Agents</a></li>
<li><a href="/mesh/tubulin-modulators">Tubulin Modulators</a></li>
<li><a href="/mesh/monoclonal-antibodies">Monoclonal antibodies</a></li></ul></td></tr><tr><th>CAS number</th><td>1018448-65-1</td></tr><tr><th>Weight</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Chemical Formula</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>InChI Key</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>InChI</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>IUPAC Name</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SMILES</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Superclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Class</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment.

</td></tr><tr><th>Pharmacodynamics</th><td>Ado-trastuzumab emtansine was evaluated in two Herceptin-responsive and one Herceptin-resistant breast tumor models. In the Herceptin-responsive models, Trastuzumab-DM1 caused complete tumor regression in all mice, whereas Herceptin alone slowed tumor growth. In the Herceptin- resistant model, Herceptin alone had no effect on tumor growth. In contrast, Trastuzumab-DM1 caused &gt;90% tumor reduction in all mice. In this Herceptin- resistant model, tumor regrowth was observed after cessation of Trastuzumab- DM1 treatment, yet regression re-occurred when dosing was resumed. The effect was specific for HER2-positive tumors. Thus the physiological effects of ado-trastuzumab emtansine are cell cycle arrest and cell death by apoptosis. </td></tr><tr><th>Mechanism of action</th><td>Ado-trastuzumab emtansine is a HER2 antibody drug conjugate. The antibody portion is trastuzumab, which is humanized anti-HER2 IgG1, and produced in the mammalian Chinese Hamster Ovary cells. The drug portion is DM1, which is a maytansine derivative that inhibits microtubules. These two portions are covalently connected by 4-[N-maleimidomethyl] cyclohexane-1-carboxylate (MCC), which is a stable thioether linker. Together MCC and DM1 are called emtansine and are produced by chemical synthesis.
Ado-trastuzumab emtansine binds to the HER2 receptor&#8217;s sub-domain IV and goes into the cell by receptor-mediated endocytosis. Lysosomes degrade ado-trastuzumab emtansine and release DM1. DM1 binds to tubulin in microtubules and inhibits microtubule function producing cell arrest and apoptosis. As well, similar to trastuzumab, in vitro studies have shown that both HER2 receptor signalling inhibition and antibody-dependent cytotoxicity are mediated by ado-trastuzumab emtansine.

</td></tr><tr><th>Absorption</th><td>The absorption/ bioavailability should be close to 100% since ado-trastuzumab emtansine is administered IV.</td></tr><tr><th>Volume of distribution</th><td><p>The volume of distribution of ado-trastuzumab emtansine is about 3.13 L.</p></td></tr><tr><th>Protein binding</th><td>DM1 has a plasma protein binding value of 93%.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Ado-trastuzumab emtansine undergoes lysosomal degradation to MCC-DM1, Lys-MCC-DM1, and DM1. All of these products are detected at low levels in the plasma. DM1 undergoes further degradation by CYP3A4 and CYP3A5, but DM1 does not induce or inhibit any of the CYP450 enzymes.
  </p></td></tr><tr><th>Route of elimination</th><td>The route of elimination has not yet been fully elucidated.</td></tr><tr><th>Half life</th><td>Ado-trastuzumab emtansine has a long half life of about 4 days.</td></tr><tr><th>Clearance</th><td><p>After IV infusion, ado-trastuzumab emtansine has a clearance of 0.68 L/day.</p></td></tr><tr><th>Toxicity</th><td>The FDA label includes a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          <span class="wishart wishart-not-available">Not Available</span> 
        </td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          <span class="wishart wishart-not-available">Not Available</span> 
        </td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          <span class="wishart wishart-not-available">Not Available</span> 
        </td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          <span class="wishart wishart-not-available">Not Available</span> 
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          <span class="wishart wishart-not-available">Not Available</span> 
        </td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          <span class="wishart wishart-not-available">Not Available</span> 
        </td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, powder, lyophilized, for solution</td><td>Intravenous</td><td>100MG </td></tr><tr><td>Injection, powder, lyophilized, for solution</td><td>Intravenous</td><td>160MG </td></tr></tbody></table></td></tr><tr><th>Prices</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Patents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Predicted Properties</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li><span class="caps">FDA</span> label.</li>
	<li>Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blattler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX: Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008 Nov 15;68(22):9280-90. doi: 10.1158/0008-5472.<span class="caps">CAN</span>-08-1776. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19010901">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D09980" target="_blank">D09980 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/kadcyla-drug.htm" target="_blank">http://www.rxlist.com/kadcyla-drug.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/mtm/ado-trastuzumab-emtansine.html" target="_blank">http://www.drugs.com/mtm/ado-trastuzumab-emtansine.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Trastuzumab_emtansine" target="_blank">Trastuzumab_emtansine <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>AHFS Codes</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB05773.pdf?1372220407">show</a>(428 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB05773.pdf?1372220407">show</a>(381 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB08879">Belimumab</a></td><td>Avoid combination due to the increased risk of belimumab associated side effects.


</td></tr><tr><td><a href="/drugs/DB00363">Clozapine</a></td><td>Avoid combination due to the increased potential for agranulocytosis. </td></tr><tr><td><a href="/drugs/DB00108">Natalizumab</a></td><td>Avoid combination due to the increased risk of infection.</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Avoid combination with phenytoin and other strong CYP3A4 inducers due to the likely increase in metabolism of ado-trastuzumab emtansine to its active component, DM1.</td></tr><tr><td><a href="/drugs/DB00337">Pimecrolimus</a></td><td>Avoid combination due to the increase in immunosuppressant side effects.

</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Avoid combination due to the increase in immunosuppressant side effects.</td></tr><tr><td><a href="/drugs/DB08895">Tofacitinib</a></td><td>Avoid combination with tofacitinib and other potent immunosuppressants due to the likely enhancement of immunosuppression.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>